Paper27192518
Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
Sisti A and 2 others. An Bras Dermatol, 2016. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. Papers, record 27192518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27192518
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunosuppressive Agents | Major topic |
| Skin Pigmentation | Major topic |
| Tacrolimus | Major topic |
| Vitiligo | Major topic |
| Administration, Cutaneous | |
| Female | |
| Humans | |
| Male | |
| Ointments | |
| Reproducibility of Results | |
| Treatment Outcome |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21352308 | Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo. | J Dermatol | 2011 | https://conductscience.org/library/papers/21352308 | PubMed |
| 2 | 18727812 | Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. | Dermatol Ther | 2008 | https://conductscience.org/library/papers/18727812 | PubMed |
| 3 | 12399684 | Repigmentation of vitiligo with topical tacrolimus. | Dermatology | 2002 | https://conductscience.org/library/papers/12399684 | PubMed |
| 4 | 12756094 | A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. | Arch Dermatol | 2003 | https://conductscience.org/library/papers/12756094 | PubMed |
| 5 | 18779885 | Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. | Acta Derm Venereol | 2008 | https://conductscience.org/library/papers/18779885 | PubMed |
| 6 | 25003059 | Concise review of recent studies in vitiligo. | Qatar Med J | 2013 | https://conductscience.org/library/papers/25003059 | PubMed |
| 7 | 21533297 | Topical tacrolimus is more effective for treatment of vitiligo in patients of skin of color. | J Drugs Dermatol | 2011 | https://conductscience.org/library/papers/21533297 | PubMed |
| 8 | 16476357 | [Vitiligo. Treatment of 12 cases with topical tacrolimus]. | Actas Dermosifiliogr | 2005 | https://conductscience.org/library/papers/16476357 | PubMed |
| 9 | 17875902 | Focal acne during topical tacrolimus therapy for vitiligo. | Arch Dermatol | 2007 | https://conductscience.org/library/papers/17875902 | PubMed |
| 10 | 24150824 | [Off-label indications for topical tacrolimus]. | Hautarzt | 2013 | https://conductscience.org/library/papers/24150824 | PubMed |
| 11 | 16120133 | FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. | Br J Dermatol | 2005 | https://conductscience.org/library/papers/16120133 | PubMed |
| 12 | 18327009 | Tacrolimus-induced hyperpigmentation in a patch of vitiligo. | Skinmed | 2008 | https://conductscience.org/library/papers/18327009 | PubMed |
| 13 | 15660910 | Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. | Pediatr Dermatol | 2005 | https://conductscience.org/library/papers/15660910 | PubMed |
| 14 | 21965863 | Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trial. | Indian J Dermatol | 2011 | https://conductscience.org/library/papers/21965863 | PubMed |
| 15 | 18789070 | Topical immunomodulators are effective for treatment of vitiligo. | J Dermatol | 2008 | https://conductscience.org/library/papers/18789070 | PubMed |
| 16 | 19496898 | Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. | J Eur Acad Dermatol Venereol | 2009 | https://conductscience.org/library/papers/19496898 | PubMed |
| 17 | 24860752 | Hyperpigmentation in photo exposed patches of vitiligo following tacrolimus therapy. | Indian Dermatol Online J | 2014 | https://conductscience.org/library/papers/24860752 | PubMed |
| 18 | 21457214 | A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. | Br J Dermatol | 2011 | https://conductscience.org/library/papers/21457214 | PubMed |
| 19 | 20175845 | Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo. | J Dermatol | 2010 | https://conductscience.org/library/papers/20175845 | PubMed |
| 20 | 15243524 | Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. | J Am Acad Dermatol | 2004 | https://conductscience.org/library/papers/15243524 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42219812 | Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025). | J Dermatol | 2026 | https://conductscience.org/library/papers/42219812 | PubMed |
| 41996020 | Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus. | Dermatol Ther (Heidelb) | 2026 | https://conductscience.org/library/papers/41996020 | PubMed |
| 40740404 | Recent Advances in Management of Vitiligo. | Indian J Dermatol | 2025 | https://conductscience.org/library/papers/40740404 | PubMed |
| 40172744 | Impacts of Topical Treatments and Phototherapy on Stratum Corneum Hydration, Sebum and Elasticity in Vitiligo Skin. | Dermatol Ther (Heidelb) | 2025 | https://conductscience.org/library/papers/40172744 | PubMed |
| 38839628 | The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review. | Inflamm Res | 2024 | https://conductscience.org/library/papers/38839628 | PubMed |
| 38178870 | Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo. | Front Cell Dev Biol | 2023 | https://conductscience.org/library/papers/38178870 | PubMed |
| 36865864 | Melanogenesis and Hypopigmentation: The Case of Vitiligo. | Indian J Dermatol | 2022 | https://conductscience.org/library/papers/36865864 | PubMed |
| 33911786 | The Role of MicroRNAs in Vitiligo: Regulators and Therapeutic Targets. | Ann Dermatol | 2020 | https://conductscience.org/library/papers/33911786 | PubMed |
| 32705792 | Macrophage inhibitory factor (MIF) gene polymorphisms are associated with disease susceptibility and with circulating MIF levels in active non-segmental vitiligo in patients from western Mexico. | Mol Genet Genomic Med | 2020 | https://conductscience.org/library/papers/32705792 | PubMed |
| 30238584 | A preliminary study of fractional CO2 laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo. | Dermatol Ther | 2019 | https://conductscience.org/library/papers/30238584 | PubMed |
| 29464168 | Treatment Strategies for Hypopigmentation in the Context of Burn Hypertrophic Scars. | Plast Reconstr Surg Glob Open | 2018 | https://conductscience.org/library/papers/29464168 | PubMed |
| 28217552 | Effectiveness and safety of topical tacrolimus in treatment of vitiligo. | J Adv Pharm Technol Res | 2017 | https://conductscience.org/library/papers/28217552 | PubMed |
| 28029168 | Trends in Regenerative Medicine: Repigmentation in Vitiligo Through Melanocyte Stem Cell Mobilization. | Med Res Rev | 2017 | https://conductscience.org/library/papers/28029168 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL3 | 3562 | PubTator's text mining | https://conductscience.org/library/genes/3562 | NCBI Gene |
| IL4 | 3565 | PubTator's text mining | https://conductscience.org/library/genes/3565 | NCBI Gene |
| IL5 | 3567 | PubTator's text mining | https://conductscience.org/library/genes/3567 | NCBI Gene |
| KITLG | 4254 | PubTator's text mining | https://conductscience.org/library/genes/4254 | NCBI Gene |
| MMP9 | 4318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27192518
GET https://conductscience.org/api/papers/v1/27192518/references?page=2